IL-17A in diabetic kidney disease: protection or damage

Hai-Bo Tan; Yan-Qiu Zheng; Yu-Pei Zhuang

doi:10.1016/j.intimp.2022.108707

IL-17A in diabetic kidney disease: protection or damage

Int Immunopharmacol. 2022 Jul:108:108707. doi: 10.1016/j.intimp.2022.108707. Epub 2022 Mar 25.

Authors

Hai-Bo Tan¹, Yan-Qiu Zheng², Yu-Pei Zhuang³

Affiliations

¹ Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, PR China. Electronic address: thb13265042784@163.com.
² Pi-Wei Institute, Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510006, PR China.
³ Department of Gastroenterology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510006, PR China.

PMID: 35344813
DOI: 10.1016/j.intimp.2022.108707

Abstract

The effect of IL-17A in diabetic kidney disease (DKD) has received increasing attention. Interleukin (IL)-17A promotes renal inflammation and the progression of DKD, and IL-17A deficiency improves experimental DKD. However, recent studies have found that the effect of IL-17A on DKD is more complicated than the negative impact. IL-17A alleviates renal inflammation and fibrosis via regulating autophagy or the macrophage phenotype. Moreover, paradoxical expression of IL-17A has been reported in human DKD. This review focuses on how IL-17A affects the progression of DKD and the resulting opportunities and challenges.

Keywords: Diabetic kidney disease; Fibrosis; IL-17A; Inflammation.

Publication types

Review

MeSH terms

Diabetes Mellitus* / pathology
Diabetic Nephropathies* / metabolism
Fibrosis
Humans
Inflammation / metabolism
Interleukin-17* / metabolism
Kidney / pathology
Macrophages / metabolism

Substances

IL17A protein, human
Interleukin-17